Elwood & Goetz Wealth Advisory Group LLC Sells 21 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Elwood & Goetz Wealth Advisory Group LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 471 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. Elwood & Goetz Wealth Advisory Group LLC’s holdings in Regeneron Pharmaceuticals were worth $336,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of REGN. Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. KBC Group NV grew its stake in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares in the last quarter. State Street Corp grew its stake in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in Regeneron Pharmaceuticals by 40.2% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock worth $204,598,000 after buying an additional 55,828 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.6 %

NASDAQ:REGN opened at $700.33 on Friday. The company has a fifty day moving average of $699.40 and a 200 day moving average of $882.47. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.56 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $11.86 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.